TeaRx Ltd.

To evaluate influence of therapy on the following efficacy and safety parameters in different TeaRx dose groups and Enoxaparin group:
Total venous thromboembolic events (VTE), which includes confirmed deep venous thrombosis (DVT), nonfatal pulmonary embolism (PE), and total mortality
Incidence of DVT (total, proximal, distal)
Incidence of nonfatal PE
Incidence of symptomatic VTE (DVT, PE)
VTE caused mortality
Non-VTE caused mortality
Incidence of all hemorrhagic complications
Incidence of major and clinically relevant non-major bleeding
Adverse events (AEs) and serious adverse events (SAEs) from subject complaints, physical examination, vital signs, laboratory results